Zobrazeno 1 - 10
of 521
pro vyhledávání: '"Fox KAA"'
Autor:
Fox, KAA, Virdone, S, Bassand, J-P, Camm, AJ, Goto, S, Goldhaber, SZ, Haas, S, Kayani, G, Koretsune, Y, Misselwitz, F, Oh, S, Piccini, JP, Parkhomenko, A, Sawhney, JPS, Stepinska, J, Turpie, AGG, Verheugt, FWA, Kakkar, AK, GARFIELD-AF investigators
OBJECTIVE: In patients with newly diagnosed atrial fibrillation (AF), do baseline risk factors and stroke prevention strategies account for the geographically diverse outcomes. DESIGN: Global Anticoagulant Registry in the FIELD-Atrial Fibrillation is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::56f81169a3f834b48e89399d8144e73e
https://openaccess.sgul.ac.uk/id/eprint/114053/1/e049933.full.pdf
https://openaccess.sgul.ac.uk/id/eprint/114053/1/e049933.full.pdf
Autor:
Boivin-Proulx, L-A, Deneault-Marchand, A, Matteau, A, Mansour, S, Gobeil, F, Camm, JA, Fox, KAA, Potter, BJ
BACKGROUND: The management of atrial fibrillation and flutter (AF) patients undergoing percutaneous coronary intervention (PCI) has undergone a rapid recent evolution. In 2016, the Canadian Cardiovascular Society (CCS) published expert recommendation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::1042f847c98f5fcfbda862d758c61470
https://openaccess.sgul.ac.uk/id/eprint/111533/1/clc.23316.pdf
https://openaccess.sgul.ac.uk/id/eprint/111533/1/clc.23316.pdf
Autor:
Fox, KAA, Velentgas, P, Camm, AJ, Bassand, J-P, Fitzmaurice, DA, Gersh, BJ, Goldhaber, SZ, Goto, S, Haas, S, Misselwitz, F, Pieper, KS, Turpie, AGG, Verheugt, FWA, Dabrowski, E, Luo, K, Gibbs, L, Kakkar, AK, GARFIELD-AF Investigators
Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::cd291dfb47b2bfedb3d7688734b6f74e
https://openaccess.sgul.ac.uk/id/eprint/111723/1/fox_2020_oi_200012.pdf
https://openaccess.sgul.ac.uk/id/eprint/111723/1/fox_2020_oi_200012.pdf
Autor:
Fox, KAA, Poole-Wilson, P, Clayton, TC, Henderson, RA, Shaw, TRD, Wheatley, DJ, Knight, R, Pocock, SJ
Publikováno v:
In The Lancet 10-16 September 2005 366(9489):914-920
Autor:
Everett, CC, Fox, KAA, Reynolds, C, Fernandez, C, Sharples, LD, Stocken, DD, Carruthers, K, Hemingway, H, Yan, AT, Goodman, SG, Brieger, D, Chew, DP, Gale, CP
Introduction For non-ST-segment elevation acute coronary syndrome (NSTEACS) there is a gap between the use of class 1 guideline recommended therapies and clinical practice. The GRACE risk score is recommended in international guidelines for the risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::105408bf49547008e0b7ac4409691989
https://eprints.whiterose.ac.uk/147983/8/e032165.full.pdf
https://eprints.whiterose.ac.uk/147983/8/e032165.full.pdf
Autor:
Beyer-Westendorf, J, Camm, AJ, Fox, KAA, Le Heuzey, J-Y, Haas, S, Turpie, AGG, Virdone, S, Kakkar, AK, Investigators, RIVERR
Background\ud Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in everyday practice. RIVER (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::6c5dc0bf679203b02db90909419fdf25
https://openaccess.sgul.ac.uk/id/eprint/110862/1/document.pdf
https://openaccess.sgul.ac.uk/id/eprint/110862/1/document.pdf
Autor:
Patel, RS, Schmidt, AF, Tragante, V, McCubrey, RO, Holmes, MV, Howe, LJ, Direk, K, Åkerblom, A, Leander, K, Virani, SS, Kaminski, KA, Muehlschlegel, JD, Dubé, M-P, Allayee, H, Almgren, P, Alver, M, Baranova, EV, Behlouli, H, Boeckx, B, Braund, PS, Breitling, LP, Delgado, G, Duarte, NE, Dufresne, L, Eriksson, N, Foco, L, Gijsberts, CM, Gong, Y, Hartiala, J, Heydarpour, M, Hubacek, JA, Kleber, M, Kofink, D, Kuukasjärvi, P, Lee, V-V, Leiherer, A, Lenzini, PA, Levin, D, Lyytikäinen, L-P, Martinelli, N, Mons, U, Nelson, CP, Nikus, K, Pilbrow, AP, Ploski, R, Sun, YV, Tanck, MWT, Tang, WHW, Trompet, S, Van Der Laan, SW, Van Setten, J, Vilmundarson, RO, Anselmi, C, Vlachopoulou, E, Boerwinkle, E, Briguori, C, Carlquist, JF, Carruthers, KF, Casu, G, Deanfield, J, Deloukas, P, Dudbridge, F, Fitzpatrick, N, Gigante, B, James, S, Lokki, M-L, Lotufo, PA, Marziliano, N, Mordi, IR, Muhlestein, JB, Newton-Cheh, C, Pitha, J, Saely, CH, Samman-Tahhan, A, Sandesara, PB, Teren, A, Timmis, A, Van De Werf, F, Wauters, E, Wilde, AAM, Ford, I, Stott, DJ, Algra, A, Andreassi, MG, Ardissino, D, Arsenault, BJ, Ballantyne, CM, Bergmeijer, TO, Bezzina, CR, Body, SC, Bogaty, P, De Borst, GJ, Brenner, H, Burkhardt, R, Carpeggiani, C, Condorelli, G, Cooper-Dehoff, RM, Cresci, S, De Faire, U, Doughty, RN, Drexel, H, Engert, JC, Fox, KAA, Girelli, D, Hagström, E, Hazen, SL, Held, C, Hemingway, H, Hoefer, IE, Hovingh, GK, Johnson, JA, De Jong, PA, Jukema, JW, Kaczor, MP, Kähönen, M, Kettner, J, Kiliszek, M, Klungel, OH, Lagerqvist, B, Lambrechts, D, Laurikka, JO, Lehtimäki, T, Lindholm, D, Mahmoodi, BK, Der Zee, AH, McPherson, R, Melander, O, Metspalu, A, Pepinski, W, Olivieri, O, Opolski, G, Palmer, CN, Pasterkamp, G, Pepine, CJ, Pereira, AC, Pilote, L, Quyyumi, AA, Richards, AM, Sanak, M, Scholz, M, Siegbahn, A, Sinisalo, J, Smith, JG, Spertus, JA, Stewart, AFR, Szczeklik, W, Szpakowicz, A, Berg, JM, Thanassoulis, G, Thiery, J, Van Der Graaf, Y, Visseren, FLJ, Waltenberger, J, Van Der Harst, P, Tardif, J-C, Sattar, N, Lang, CC, Paré, G, Brophy, JM, Anderson, JL, März, W, Wallentin, L, Cameron, VA, Horne, BD, Samani, NJ, Hingorani, AD, Asselbergs, FW
Genetic variation at chromosome 9p21 is a recognized risk factor for coronary heart disease (CHD). However, its effect on disease progression and subsequent events is unclear, raising questions about its value for stratification of residual risk.A va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::86d67053a6d54128f7e80f8f66460c21
http://hdl.handle.net/11562/1028981
http://hdl.handle.net/11562/1028981
BACKGROUND: Four nonvitamin K antagonist oral anticoagulants (NOACs) have been approved for use in various cardiovascular indications. The direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors apixaban, edoxaban, and rivaroxaban ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::a8103e0777538a543cbfa38885c5567b